Abbott Labs: Genes Aren't The Only Thing That Can Effectively Be Spliced Seeking Alpha One such drug is Daclizumab. Abbott just reported positive Phase 2b trial results for the drug in treating multiple sclerosis. Patients enrolled in the study saw up to a 54% reduction in annualized relapse. This is impressive given it's a once a month ... |
